Lipocine (LPCN) Cash from Financing Activities (2011 - 2025)

Lipocine (LPCN) has 15 years of Cash from Financing Activities data on file, last reported at $141334.0 in Q3 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $141334.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $358774.0 (up 75.83% YoY) and the FY2024 annual result came in at $209340.0, down 48.26% from the prior year.
• Cash from Financing Activities eased to $141334.0 in Q3 2025, from $217440.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $29.4 million in Q1 2021 to a low of -$1.5 million in Q2 2022.
• A 5-year average of $1.7 million and a median of -$5900.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 118.41% — and 2023, when it surged 956904.55%.
• Tracing LPCN's Cash from Financing Activities over 5 years: stood at -$838463.0 in 2021, then jumped by 99.3% to -$5900.0 in 2022, then gained by 10.19% to -$5299.0 in 2023, then surged by 4203.42% to $217440.0 in 2024, then slumped by 35.0% to $141334.0 in 2025.
• The last three Cash from Financing Activities figures came in at $141334.0 (Q3 2025), $217440.0 (Q2 2024), and -$8100.0 (Q1 2024), per Business Quant data.